Background: The aim of this study was to characterize the anticonvulsant effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline (1-MeTHIQ) in combination with clobazam (CLB) in the mouse maximal electroshock-induced seizure (MES) model. Methods: The anticonvulsant interaction profile between 1-MeTHIQ and CLB in the mouse MES model was determined using an isobolographic analysis for parallel dose-response relationship curves. Results: Electroconvulsions were produced in albino Swiss mice by a current (sine wave, 25 mA, 500 V, 50 Hz, 0.2-second stimulus duration) delivered via auricular electrodes by a Hugo Sachs generator. There was an additive effect of the combination of 1-MeTHIQ with CLB (at the fixed ratios of 1:3, 1:1 and 3:1) in the mouse MES-induced tonic seizure model. Conclusions: The additive interaction of the combination of 1-MeTHIQ with CLB (at fixed-ratios of 1:3, 1:1 and 3:1) in the mouse MES model seems to be pharmacodynamic in nature and worth of considering in further clinical practice.

1.
Antkiewicz-Michaluk L, Wąsik A, Romańska I, Bojarski A, Michaluk J: Both stereoselective (R)- and (S)-1-methyl-1,2,3,4-tetrahydroisoquinoline enantiomers protect striatal terminals against rotenone-induced suppression of dopamine release. Neurotox Res 2011;20:134-149.
2.
Antkiewicz-Michaluk L, Karolewicz B, Romanska I, Michaluk J, Bojarski AJ, Vetulani J: 1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. Eur J Pharmacol 2003;466:263-269.
3.
Antkiewicz-Michaluk L, Wardas J, Michaluk J, Romaska I, Bojarski A, Vetulani J: Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. Int J Neuropsychopharmacol 2004;7:155-163.
4.
Antkiewicz-Michaluk L, Lazarewicz JW, Patsenka A, Kajta M, Zieminska E, Salinska E, Wasik A, Golembiowska K, Vetulani J: The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. J Neurochem 2006;97:846-856.
5.
Pietraszek M, Michaluk J, Romańska I, Wasik A, Gołembiowska K, Antkiewicz-Michaluk L: 1-Methyl-1,2,3,4-tetrahydroisoquinoline antagonizes a rise in brain dopamine metabolism, glutamate release in frontal cortex and locomotor hyperactivity produced by MK-801 but not the disruptions of prepulse inhibition, and impairment of working memory in rat. Neurotox Res 2009;16:390-407.
6.
Antkiewicz-Michaluk L, Filip M, Michaluk J, Romańska I, Przegaliński E, Vetulani J: An endogenous neuroprotectant substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats. J Neural Transm 2007;114:307-317.
7.
Luszczki JJ, Antkiewicz-Michaluk L, Czuczwar SJ: 1-Methyl-1,2,3,4-tetrahydroisoquinoline enhances the anticonvulsant action of carbamazepine and valproate in the mouse maximal electroshock seizure model. Neuropharmacology 2006;50:133-142.
8.
Luszczki JJ, Antkiewicz-Michaluk L, Czuczwar SJ: Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Eur J Pharmacol 2009;602:298-305.
9.
Luszczki JJ, Antkiewicz-Michaluk L, Raszewski G, Czuczwar SJ: Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: a type I isobolographic analysis. Epilepsy Res 2010;89:207-219.
10.
Andres-Mach M, Zadrożniak A, Haratym-Maj A, Raszewski G, Antkiewicz-Michaluk L, Luszczki JJ: Effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on the protective action of various antiepileptic drugs in the maximal electroshock-induced seizure model: a type II isobolographic analysis. J Neural Transm 2013;120:1651-1663.
11.
Larrieu JL, Lagueny A, Ferrer X, Julien J: Epilepsy with continuous discharges during slow-wave sleep. Treatment with clobazam (in French). Rev Electroencephalogr Neurophysiol Clin 1986;16:383-394.
12.
Gastaut H, Tinuper P, Aguglia U, Lugaresi E: Treatment of certain forms of status epilepticus by means of a single oral dose of clobazam (in French). Rev Electroencephalogr Neurophysiol Clin 1984;14:203-206.
13.
Shimizu H, Kawasaki J, Yuasa S, Tarao Y, Kumagai S, Kanemoto K: Use of clobazam for the treatment of refractory complex partial seizures. Seizure 2003;12:282-286.
14.
Sanofi-Aventis. Frisium tablets 10 mg, summary of product characteristics from eMC. Electronic Medicines Compendium. Medicines.org.uk, 2002 (accessed July 11, 2005).
15.
Isojärvi JI, Tokola RA: Benzodiazepines in the treatment of epilepsy in people with intellectual disability. J Intellect Disabil Res 1998;42(suppl 1):80-92.
16.
Luszczki JJ, Borowicz KK, Swiader M, Czuczwar SJ: Interactions between oxcarbazepine and conventional antiepileptic drugs in the maximal electroshock test in mice: an isobolographic analysis. Epilepsia 2003;44:489-499.
17.
Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96:99-113.
18.
Luszczki JJ, Czuczwar SJ: Interaction between lamotrigine and felbamate in the maximal electroshock-induced seizures in mice: an isobolographic analysis. Eur Neuropsychopharmacol 2005;15:133-142.
19.
Loewe S: The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 1953;3:285-290.
20.
Porreca F, Jiang Q, Tallarida RJ: Modulation of morphine antinociception by peripheral [Leu5]enkephalin: a synergistic interaction. Eur J Pharmacol 1990;179:463-468.
21.
Ng YT, Collins SD: Clobazam. Neurotherapeutics 2007;4:138-144.
22.
Doi T, Ueda Y, Tokumaru J, Willmore LJ: Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats. Brain Res Mol Brain Res 2005;142:91-96.
23.
Nakajima H: A pharmacological profile of clobazam (Mystan), a new antiepileptic drug (in Japanese). Nihon Yakurigaku Zasshi 2001;118:117-122.
24.
Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L: Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br J Clin Pharmacol 1990;29:169-177.
25.
McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, Farrar S, Myers J, et al: Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci 2000;3:587-592.
26.
Nakamura F, Suzuki S, Nishimura S, Yagi K, Seino M: Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia 1996;37:728-735.
27.
Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A: Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther Drug Monit 2002;24:737-741.
28.
Cui D, Tran A, Rey E, Vincent J, Tréluyer JM, Pons G: In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004;32:1279-1286.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.